Follow
loriot y
loriot y
Verified email at gustaveroussy.fr
Title
Cited by
Cited by
Year
Abiraterone and increased survival in metastatic prostate cancer
JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ...
New England Journal of Medicine 364 (21), 1995-2005, 2011
49752011
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
B Routy, E Le Chatelier, L Derosa, CPM Duong, MT Alou, R Daillère, ...
Science 359 (6371), 91-97, 2018
43222018
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
S Mariathasan, SJ Turley, D Nickles, A Castiglioni, K Yuen, Y Wang, ...
Nature 554 (7693), 544-548, 2018
36652018
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm …
JE Rosenberg, J Hoffman-Censits, T Powles, MS Van Der Heijden, ...
The Lancet 387 (10031), 1909-1920, 2016
36592016
Enzalutamide in metastatic prostate cancer before chemotherapy
TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
New England Journal of Medicine 371 (5), 424-433, 2014
32972014
Early childhood development coming of age: science through the life course
MM Black, SP Walker, LCH Fernald, CT Andersen, AM DiGirolamo, C Lu, ...
The Lancet 389 (10064), 77-90, 2017
26492017
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
T Powles, JP Eder, GD Fine, FS Braiteh, Y Loriot, C Cruz, J Bellmunt, ...
Nature 515 (7528), 558-562, 2014
25692014
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ...
The Lancet 389 (10064), 67-76, 2017
20532017
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 …
T Powles, I Durán, MS Van der Heijden, Y Loriot, NJ Vogelzang, ...
The Lancet 391 (10122), 748-757, 2018
13422018
Erdafitinib in locally advanced or metastatic urothelial carcinoma
Y Loriot, A Necchi, SH Park, J Garcia-Donas, R Huddart, E Burgess, ...
New England Journal of Medicine 381 (4), 338-348, 2019
10762019
Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma
T Powles, SH Park, E Voog, C Caserta, BP Valderrama, H Gurney, ...
New England Journal of Medicine 383 (13), 1218-1230, 2020
9742020
High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial
C Massard, S Michiels, C Ferté, MC Le Deley, L Lacroix, A Hollebecque, ...
Cancer discovery 7 (6), 586-595, 2017
6552017
Enfortumab vedotin in previously treated advanced urothelial carcinoma
T Powles, JE Rosenberg, GP Sonpavde, Y Loriot, I Durán, JL Lee, ...
New England Journal of Medicine 384 (12), 1125-1135, 2021
6042021
Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study
TM Beer, AJ Armstrong, D Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
European urology 71 (2), 151-154, 2017
4522017
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
J Rodon, JC Soria, R Berger, WH Miller, E Rubin, A Kugel, A Tsimberidou, ...
Nature medicine 25 (5), 751-758, 2019
4142019
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
Y Loriot, D Bianchini, E Ileana, S Sandhu, A Patrikidou, C Pezaro, ...
Annals of oncology 24 (7), 1807-1812, 2013
4132013
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ...
The Lancet Oncology 22 (7), 931-945, 2021
3922021
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma …
T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ...
The Lancet Oncology 21 (12), 1574-1588, 2020
3772020
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
D Planchard, Y Loriot, F Andre, A Gobert, N Auger, L Lacroix, JC Soria
Annals of Oncology 26 (10), 2073-2078, 2015
3252015
TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint …
ST Tagawa, AV Balar, DP Petrylak, AR Kalebasty, Y Loriot, A Fléchon, ...
Journal of Clinical Oncology 39 (22), 2474, 2021
3102021
The system can't perform the operation now. Try again later.
Articles 1–20